L2086F Mutant ROS1-Rearranged NSCLC Resistant to Repotrectinib Responds to Cabozantinib: A Case Report.

Repotrectinib, licensed in November 2023, is a novel ROS1 tyrosine kinase inhibitor (TKI) with activity against , the most common resistance mutation to prior generations of ROS1 TKIs. Here, we report a case of a patient who was heavily pretreated, with advanced and mutated rearranged NSCLC, who initially responded to repotrectinib but later developed further on-target resistance with the emergence of an mutation. The disease then responded to cabozantinib, a separate class of ROS1 TKI with preclinical activity against .